Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(35)
•••
Comment by Gustoeson Jan 07, 2016 10:44pm
166 Views
Post# 24439021

RE:RE:RE:Melanoma: New Zealand not covering Merck's blockbuster drug

RE:RE:RE:Melanoma: New Zealand not covering Merck's blockbuster drug
bencro wrote: It's always a question of what else is more efficient and available ... ;-)

... Our findings suggest that it could generate as much as $5 billion in revenues for the company

How Significant Can Keytruda Be For Merck?

Currently in 131 clinical trials ...

Nothing will beat PDT/PDC both in patient-care, patient quality of life, time, costs and efficiency if we're able to replicates animal models data.  Public Health systems will jump on this technology.


Bingo. Both pain management/tissue related therapies and cancer treatment standards are about to be revolutionized by PDT treatments and delivery systems. It will at some point in the next 1-5 years reach critical mass and adoption by health care providers/insurers... TLT could be at the forefront. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities